Antinociceptive properties of chloromaleinimides and their sulphonyl derivatives

This report describes the synthesis of new cyclic imides obtained from the reaction between aniline and dichloromaleic anhydride with further chlorosulphonation as well as the reaction between different amines and 4-methoxyphenol for the synthesis of imidobenzenesulphonyl derivatives. These compounds were tested as antinociceptive agents using the writhing test on mice. Some compounds, when intraperitoneally injected, proved to be potent and dose-related antinociceptives, being several times more active than many known reference drugs.     

Microcalorimetric investigations of drug-albumin interactions

Flow microcalorimetry was used to estimate primary binding constants for drug-albumin interactions. Measurements of heat of reaction at two temperatures illustrated the danger of extrapolation for pharmacokinetic purposes of measurements made at temperatures other than 37 degrees. The method could be used to predict competition between two drugs for a single binding site. Major advantages over spectroscopic techniques included direct determinations of thermodynamic parameters, and the use of physiological concentrations of albumin.     

Sulphonamide Antibodies: From Specific Polyclonals to Generic Monoclonals

Polyclonal antibodies (PAbs) against eight different sulphonamides were raised in rabbits. The aromatic amino group, common to all sulphonamides, was used for linking the different sulphonamides to the carrier proteins (bovine serum albumin (BSA) and keyhole limpet haemocyanin (KLH)) and enzyme (horseradish peroxidase (HRP)), using different coupling procedures. The competitive direct ELISAs (cdELISAs) developed with these antisera and HRP-conjugates showed high sensitivity (0.2- 8.0 ng ml^-1 at 50% inhibition) and high specificity. The performances of these antibodies were compared with PAbs raised in mice against two sulphonamide derivatives (N¹ -[4-(carboxymethyl)-2-thiazolyl]sulphanilamide (TS) and N¹-[4-methyl-5-\[2-(4-carboxyethyl-1-hydroxyphenyl)]-azo-2-pyridyl]sulphanilamide (PS)) linked to proteins (BSA and KLH) in such a way that the common aromatic amino group was distal to the protein. In competitive indirect ELISAs (ciELISAs), these PAbs recognized several structurally different sulphonamides. The PAbs from mice immunized with TS-BSA reacted with sulphonamides containing thiazolyl, thiadiazolyl, pyridazinyl and isoxazolyl groups. The PAbs from mice immunized with PS-KLH reacted with sulphonamides containing pyrimidinyl, pyridazinyl, quinoxalinyl and pyridinyl groups. The spleen cells of the mice were fused with myeloma cells to obtain monoclonal antibodies (MAbs) producing hybridomas. So far, with only one of the mice (immunized with TS-BSA), this resulted in four different MAbs which recognized several sulphonamides. By use of the best MAbs (27G3A9B10 and 4E10B12B6E12) and an optimized ciELISA protocol, eight structurally different sulphonamides showed 50% inhibition at concentrations less than 100 ng ml^-1 or 5 ng/well. However, other relevant sulphonamides (such as sulphadimidine, sulphatroxazole and sulphachloropyrazine) were detected at a high level only.     

Pharmacokinetics of sulfametopyrazine (Kelfizine W) effects of a single oral dose

Summary The pharmacokinetics of sulfametopyrazine were studied for seven days after a single oral dose of 2 g. in healthy volunteers in order to establish its chemotherapeutic value. — The appearance and disappearance of the drug in the plasma were evaluated both for compounds with a free amino group and for total sulphonamides. The half-life and absorption, distribution, elimination and excretion coefficients were calculated, as well as the concentrations in plasma water and interstitial fluid. The estimated drug concentrations in the urine agreed with those calculated from the excretion coefficients. — In all subjects at the end of the seventh day the concentrations in all body compartments of active compounds exceeded the minimum required for a therapeutic effect. The highest concentrations found in the urine were always significantly lower than the drug's basal solubility at pH 5, thus excluding any risk of crystalluria.Glossary of symbols total binding capacity of plasma proteins for SMP - Specific gravity of blood ( Bl), and interstitial fluid (IF) - minimum inhibitory concentration for bacterial growth. Evaluation of against E. coli or other pathogenic bacteria in a medium free of antagonists [29] - ratio of dose interval to half-life - dose interval - safety factor. Proportionality constant between andc _min for a therapeutic efficacy of 95 per cent - fraction of the administered drug absorbed from the depot (gastrointestinal tract etc.) - distribution coefficient with respect to the drug concentration in blood plasma (ml/g) - D* initial dose of the drug - D maintenance dose - M molecular weight of the drug (280) - G weight of subject (kg) - F area between time axis and concentration curve (plotted c' values) - t _50% apparent biological half-life - w ¹ water content of plasma (ml/ml) - p protein concentration of plasma (pBl), or interstitial fluid (pIF) (g/l) - c _IF concentration in the interstitial fluid - C ₀ concentration in plasma at zero time after i.v. administration - c ₁ ⁰ concentration in plasma after oral absorption extrapolated to zero time - c ₁ concentration in plasma water of the drug with free amino function - c _min minimum inhibitory concentration needed in plasma water (minimum therapeutic concentration) - k ₀₁ rate constant for absorption - k ₁ rate constant for absorption determined at timet; (similarlyk₂) - K total elimination coefficient - k _el rate constant for elimination - k _F rate constant for formation of metabolites - k _D excretion coefficient of SMP with free amino function - k _U coefficient of metabolite excretion - D ₀ quantity of SMP in the body at time zero - D _B quantity of SMP in the body at timet - D _U quantity of SMP excreted in the urine at timet - M _F quantity of metabolites formed at timet - M _B quantity of metabolites present in the body at timet - M _U quantity of metabolites excreted in the urine at timet - K dissociation constant for the sulphonamide-protein complex - notation for quantities related to drug concentrations in plasma, e.g. c (corresponding term without refer to plasma water)     

Indirect continuous automatic determination of pharmaceuticals by atomic absorption spectroscopy

The implementation of continuous separation techniques such as precipitation, liquid—liquid and solid—liquid extraction in FIA manifolds coupled on-line with an atomic absorption spectrometer for the determination of active components (sulphonamides, local anaesthetics, amphetamines, benzodiazepines, chloramphenicol and methadone) in pharmaceuticals and biological fluids is systematically described. The basic features of the analytical methodologies described (sensitivity, selectivity, precision and rapidity) are also discussed and critically compared.